Madrigal Pharmaceuticals Inc (MDGL) Upgraded to Hold at ValuEngine
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) traded down 0.19% during midday trading on Friday, hitting $16.16. 1,744 shares of the stock were exchanged. Madrigal Pharmaceuticals has a 1-year low of $6.60 and a 1-year high of $18.24. The company’s market capitalization is $196.62 million. The firm has a 50-day moving average of $15.89 and a 200-day moving average of $15.86.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Thursday, May 11th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.37. On average, equities analysts expect that Madrigal Pharmaceuticals will post ($2.57) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Madrigal Pharmaceuticals Inc (MDGL) Upgraded to Hold at ValuEngine” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/05/19/madrigal-pharmaceuticals-inc-mdgl-upgraded-to-hold-at-valuengine.html.
Several institutional investors have recently bought and sold shares of MDGL. Goldman Sachs Group Inc. acquired a new position in Madrigal Pharmaceuticals during the first quarter worth about $321,000. Citadel Advisors LLC purchased a new position in shares of Madrigal Pharmaceuticals during the third quarter valued at $332,000. Geode Capital Management LLC increased its position in shares of Madrigal Pharmaceuticals by 0.8% in the first quarter. Geode Capital Management LLC now owns 25,821 shares of the biopharmaceutical company’s stock valued at $397,000 after buying an additional 216 shares in the last quarter. Baker BROS. Advisors LP purchased a new position in shares of Madrigal Pharmaceuticals during the third quarter valued at $732,000. Finally, Renaissance Technologies LLC increased its position in shares of Madrigal Pharmaceuticals by 8.5% in the fourth quarter. Renaissance Technologies LLC now owns 57,475 shares of the biopharmaceutical company’s stock valued at $856,000 after buying an additional 4,488 shares in the last quarter. 8.72% of the stock is currently owned by institutional investors.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.